SCHEMBL2228401

SCHEMBL2228401

O=C(OCc1cscn1)N1CCC(CCOc2ccc3ncccc3c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
RAB9A P51151 7/20 0.47
LMNA P02545 3/20 0.47
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 2/20 0.46
TNF P01375 1/20 0.46
NOD1 Q9Y239 1/20 0.46
NR2F2 P24468 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 2/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
GALR3 O60755 1/20 0.41
ATM Q13315 1/20 0.41
CYP2D6 P10635 1/20 0.41
GRIN2B Q13224 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229045 0.90 MMP2 (0.45) RAB9AMMP2MMP9GRIN2BNPC1
SCHEMBL2228170 0.87 MMP2 (0.47) MAPTRAB9ALMNAMMP2MMP9
SCHEMBL2227230 0.86 GRIN2B (0.44) MAPTLMNAALDH1A1KDM4EMMP2
SCHEMBL2228462 0.85 MMP2 (0.40) MMP2MMP9CYP2D6GRIN2B
SCHEMBL2227262 0.84 MMP2 (0.41) MMP2MMP9CYP2D6GRIN2B
SCHEMBL2229024 0.84 GRIN2B (0.42) MAPTLMNAALDH1A1KDM4EMMP2
SCHEMBL2227876 0.84 MAPT (0.49) MAPTRAB9ALMNAALDH1A1KDM4E
SCHEMBL2229512 0.83 MAPT (0.50) MAPTRAB9ALMNAALDH1A1KDM4E
SCHEMBL2227489 0.83 MMP2 (0.42) MMP2MMP9GRIN2B
SCHEMBL2229979 0.83 MMP2 (0.41) MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US claimed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP claimed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US claimed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO claimed
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 MAPT 4506/4885RAB9A 443/4885LMNA 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.